Second-Generation Obesity Drugs: How Semaglutide, Tirzepatide, and Setmelanotide Compare
Second-generation anti-obesity peptide medications achieve average 15% weight loss — far surpassing first-generation drugs — with semaglutide 2.4 mg and tirzepatide also effectively treating concurrent type 2 diabetes.
Quick Facts
What This Study Found
Second-generation anti-obesity medications achieve ~15% average weight loss with lifestyle modifications. Three approved drugs: setmelanotide (monogenic obesity), semaglutide 2.4 mg, and tirzepatide. Semaglutide and tirzepatide are particularly effective when treating concurrent obesity and T2D.
Key Numbers
Average weight loss of ~15% with lifestyle modifications. Three approved drugs reviewed: setmelanotide, semaglutide 2.4 mg, and tirzepatide.
How They Did This
Narrative review examining clinical trial data and therapeutic implications of the three approved second-generation anti-obesity medications.
Why This Research Matters
Obesity affects over 40% of US adults and first-generation medications offered only modest weight loss. The 15% average weight reduction achieved by these peptide drugs is clinically meaningful — enough to significantly reduce cardiovascular risk, improve diabetes control, and reduce the need for bariatric surgery.
The Bigger Picture
These peptide-based obesity drugs represent a paradigm shift — for the first time, medications can achieve weight loss approaching that of bariatric surgery. This has transformed obesity from a condition with limited medical options to one with multiple effective pharmacological treatments.
What This Study Doesn't Tell Us
Short review with limited abstract detail. Doesn't discuss cost, access barriers, or long-term safety. Weight regain upon discontinuation not addressed. Setmelanotide applies only to rare monogenic obesity. Real-world effectiveness may differ from clinical trial results.
Questions This Raises
- ?How do the next-generation drugs (survodutide, retatrutide) compare to current options?
- ?What strategies can maintain weight loss after drug discontinuation?
- ?How should clinicians choose between semaglutide and tirzepatide for individual patients?
Trust & Context
- Key Stat:
- ~15% weight loss Second-generation anti-obesity peptide drugs achieve about 15% average weight loss with lifestyle modifications, far exceeding first-generation medications
- Evidence Grade:
- Rated strong: review synthesizing robust clinical trial evidence for all three approved medications, published in a diabetes specialty journal.
- Study Age:
- Published in 2024. Covers the current approved landscape of peptide-based anti-obesity medications.
- Original Title:
- Using Second-Generation Anti-Obesity Medications.
- Published In:
- Diabetes spectrum : a publication of the American Diabetes Association, 37(4), 303-312 (2024)
- Authors:
- Schmitz, Sarah H(2), Aronne, Louis J(7)
- Database ID:
- RPEP-09222
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are the best weight loss medications available now?
The three approved second-generation anti-obesity drugs are semaglutide 2.4 mg (Wegovy), tirzepatide (Zepbound), and setmelanotide (for rare genetic obesity). Semaglutide and tirzepatide achieve about 15% average weight loss and also help with type 2 diabetes.
How much weight can you lose with semaglutide or tirzepatide?
On average, about 15% of body weight when combined with lifestyle changes. Some patients lose more. Both drugs are peptide-based medications that work on gut hormone pathways to reduce appetite and improve metabolism.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09222APA
Schmitz, Sarah H; Aronne, Louis J. (2024). Using Second-Generation Anti-Obesity Medications.. Diabetes spectrum : a publication of the American Diabetes Association, 37(4), 303-312. https://doi.org/10.2337/dsi24-0002
MLA
Schmitz, Sarah H, et al. "Using Second-Generation Anti-Obesity Medications.." Diabetes spectrum : a publication of the American Diabetes Association, 2024. https://doi.org/10.2337/dsi24-0002
RethinkPeptides
RethinkPeptides Research Database. "Using Second-Generation Anti-Obesity Medications." RPEP-09222. Retrieved from https://rethinkpeptides.com/research/schmitz-2024-using-secondgeneration-antiobesity-medications
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.